Vitrolife

Vitrolife Current Liabilities

The Current Liabilities of Vitrolife (VITR.ST) as of Nov 10, 2026 is 806.00 M SEK. In the previous year, Current Liabilities was 990.00 M SEK — a change of -18.59% (lower).

Current Liabilities

806.00 MSEK

YoY

-18.59%

Last updated:

Current Liabilities of Vitrolife is 2025 806.00 M SEK. Current Liabilities of Vitrolife was 2024 990.00 M SEK. It decreases by -18.59% lower compared to the previous year.

The Vitrolife Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
152.17 M SEK
Jan 1, 2019
209.00 M SEK
Jan 1, 2020
196.59 M SEK
Jan 1, 2021
1.55 B SEK
Jan 1, 2022
864.00 M SEK
Jan 1, 2023
798.00 M SEK
Jan 1, 2024
990.00 M SEK
Jan 1, 2025
806.00 M SEK
The Vitrolife Current Liabilities history
YEARCurrent LiabilitiesYoY
806.00 MSEK-18.59%
990.00 MSEK+24.06%
798.00 MSEK-7.64%
864.00 MSEK-44.43%
1.55 BSEK+690.94%
196.59 MSEK-5.94%
209.00 MSEK+37.34%
152.17 MSEK+11,705.51%
1.29 MSEK-98.01%
64.92 MSEK-223.38%
-52.62 MSEK-141.18%
127.79 MSEK+4.38%
122.43 MSEK+4.78%
116.84 MSEK+34.55%
86.84 MSEK-23.41%
113.38 MSEK+391.03%
23.09 MSEK-66.12%
68.15 MSEK+31.47%
51.84 MSEK+11.31%
46.57 MSEK+52.36%
30.57 MSEK+7.74%
28.37 MSEK-17.98%
34.59 MSEK-60.77%
88.18 MSEK+46.42%
60.22 MSEK+35.47%
44.45 MSEK+250.02%
12.70 MSEK-7.30%
13.70 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vitrolife Stock analysis

What does Vitrolife do? Vitrolife AB is a Swedish biotech company specializing in the development and marketing of products for in vitro fertilization (IVF) and regenerative medicine. It was founded in 1994 and has over 390 employees worldwide. The company's main business is IVF, offering a wide range of essential products for IVF treatment such as culture media, devices for semen analysis and preparation, embryo transfer techniques, and products for biopsy examinations and cryopreservation. Vitrolife has a presence in 110 countries and has expanded its market to China where there is a high demand for fertility treatments. The company also offers medical equipment for regenerative treatments. Vitrolife is a leading player in the IVF industry known for its high product quality and innovation. It collaborates with universities and research institutions globally to improve IVF technology and success rates. The company places importance on sustainability and environmental protection, using 100% animal-free ingredients in their culture media and practicing recycling and waste reduction in their production facilities. In summary, Vitrolife offers a wide range of products for IVF and regenerative medicine, with a focus on supporting IVF treatments. The company is a leader in its industry and actively participates in research. It is committed to sustainability and environmental responsibility. Vitrolife is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vitrolife stock

Current Liabilities of Vitrolife is 806.00 M SEK in 2025.

Current Liabilities of Vitrolife changed from 990.00 M SEK to 806.00 M SEK, representing a -18.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Vitrolife since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Vitrolife historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Vitrolife

All Key Metrics — Vitrolife